Answers are grounded in this paper and cite their sources.
Real-world efficacy and safety of glofitamab salvage therapy in relapsed aggressive B-cell lymphoma indicates strong outcomes.
T-cell expansion (p = 0.02). Overall, glofitamab demonstrated durable efficacy and a manageable safety profile in R/R aggressive B-cell lymphoma, with treatment outcomes closely associated with T-cell functional status, supporting its potential as an effective bridging strategy before CAR-T therapy.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: